CTOs on the Move

Selecta Biosciences

www.selectabio.com

 
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is seeking to unlock the full potential of biologic therapies by avoiding unwanted immune responses. Selecta`s tolerogenic Synthetic Vaccine Particles (SVP™) technology platform is designed to enable a range of novel biologics for rare and serious diseases that require new treatment options. The company`s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company`s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta`s clinical oncology candidate, LMB-100, is in a Phase 1 program ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Selecta Biosciences raised $38M on 09/07/2015

Similar Companies

Threshold Pharmaceuticals

Threshold Pharmaceuticals, Inc. is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Memgen

Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression. Our integrated epigenetics platform enables us to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. We are able to target a broad variety of epigenetic regulators using our platform and have generated development candidates acting against distinct classes of those regulators.

VLST

VLST is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Singular Genomics

Singular Genomics is pushing sequencing further to bring fast, powerful and flexible tools for research and medicine. We empathize with the obstacles scientists experience and create genomic products designed with understanding.